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Abstract
Background: Immunotherapy with monoclonal antibodies that target amyloid beta has been under investigation
as a treatment for patients with Alzheimer’s disease (AD). The 3000 and 3001 phase 3 clinical studies of intravenous
bapineuzumab assessed safety and efficacy in patients with mild to moderate AD recruited in over 26 countries.
This article describes the long-term safety and tolerability of bapineuzumab in the extension studies for these two
protocols.
Methods: The long-term safety and tolerability of intravenous-administered bapineuzumab in patients with AD was
evaluated in apolipoprotein E ε4 allele noncarriers (Study 3002, extension of Study 3000) and apolipoprotein E ε4
allele carriers (Study 3003, extension of Study 3001). Those receiving bapineuzumab in the parent study were
continued at the same dose; if receiving placebo, patients began bapineuzumab. Bapineuzumab doses were 0.
5 mg/kg in both studies and also 1.0 mg/kg in the noncarrier study. Clinical efficacy of bapineuzumab was also
assessed in exploratory analyses.
Results: Because of lack of efficacy in two other phase 3 trials, the parent protocols were stopped early. As a result,
Studies 3002 and 3003 were also terminated. In total, 492 and 202 patients were enrolled in Studies 3003 and 3002,
respectively. In apolipoprotein E ε4 carriers (Study 3003), treatment-emergent adverse events occurred in 70.7 % of
the patients who originally received placebo and 66.9 % of those who originally received bapineuzumab. In noncarriers,
treatment-emergent adverse events occurred in 82.1 % and 67.6 % of patients who received placebo + bapineuzumab
0.5 mg/kg and placebo + bapineuzumab 1.0 mg/kg, respectively, and in 72.7 % and 64.3 % of those who received
bapineuzumab + bapineuzumab 0.5 mg/kg and 1.0 mg/kg, respectively. Amyloid-related imaging abnormalities with
edema or effusions were the main bapineuzumab-associated adverse events in both studies, occurring in approximately
11 % of placebo + bapineuzumab and 4 % of bapineuzumab + bapineuzumab groups overall. Exploratory analyses of
clinical efficacy were not significantly different between groups in either study.
Conclusions: In these phase 3 extension studies, intravenous bapineuzumab administered for up to approximately
3 years showed no unexpected safety signals and a safety profile consistent with previous bapineuzumab trials.
Trial registration: Noncarriers (Study 3002): ClinicalTrials.gov NCT00996918. Registered 14 October 2009.
Carriers (Study 3003): ClinicalTrials.gov NCT00998764. Registered 16 October 2009.
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Background
Alzheimer’s disease (AD) is characterized by a progressive
decline in cognitive function and an increase in functional
impairment [1–3]. Although the exact etiology of AD re-
mains unknown, overproduction or inadequate clearance
of accumulated amyloid-beta (Aβ) peptide is thought to be
an essential component in its pathophysiology [1, 2, 4, 5].
One of the therapeutic approaches to halting disease pro-
gression in AD is passive immunotherapy with monoclo-
nal antibodies (mAbs) directed against Aβ, which are
thought to reduce Aβ accumulation and promote its clear-
ance from the brain [4, 6]. This approach was shown to re-
duce cerebral Aβ deposits, improve behavioral measures,
and reverse memory loss in animal models (reviewed in
[2]), suggesting that removal of Aβ from the brain using
mAbs may provide similar benefits in humans with AD.
Bapineuzumab, a humanized mAb specific to the Aβ1–42
protein, has been evaluated in a total of four similarly de-
signed phase 3 clinical trials for the treatment of patients
with AD [6, 7]. As a result of phase 2 findings of amyloid-
related imaging abnormalities with edema or effusions
(ARIA-E), the bapineuzumab phase 3 development pro-
gram stratified patients according to apolipoprotein E
(ApoE) ε4 allele status (carriers or noncarriers) [8]. ARIA-
E are detected as an increased signal intensity on FLAIR
or other T2-weighted magnetic resonance imaging (MRI)
sequences, and are thought to arise from an increase in
permeability of brain capillaries to serum proteins, leading
to extravasation of fluid into the extracellular space [9]. In-
cidence of ARIA-E was dose dependent, and 10 of the 12
cases were observed in ApoE ε4 carriers in the phase 2
study [8], which guided dose selection for the phase 3 tri-
als in carriers and noncarriers. Studies 301 (noncarriers)
and 302 (carriers) were conducted primarily in the United
States, and Studies 3000 (noncarriers) and 3001 (carriers)
were conducted at sites in more than 26 countries to
evaluate the efficacy of intravenous (i.v.) bapineuzumab or
placebo in patients with mild to moderate AD [7]. In the
first two of these studies to be reported (Studies 301 and
302), no significant difference was found between the
bapineuzumab and placebo groups in the primary clinical
efficacy endpoints (Alzheimer’s Disease Assessment
Scale—Cognitive Subscale (ADAS-Cog/11) and Disability
Assessment Scale for Dementia (DAD)) [7]. ARIA-E were
a primary safety finding in these studies in patients treated
with bapineuzumab [7]. Based on the lack of clinical effi-
cacy observed in the 301 and 302 studies, all ongoing
bapineuzumab trials were terminated early by the spon-
sors in August 2012 [7]. Results from the terminated
phase 3 parent studies (3000 and 3001) were presented in
2013 at the Clinical Trials on Alzheimer’s Disease sympo-
sium; consistent with the results of Studies 301 and 302,
neither showed a clinical benefit of bapineuzumab
therapy.
In this report, we detail findings from the 3002 and
3003 phase 3 extension studies of bapineuzumab in pa-
tients with AD who participated in the respective parent
studies 3000 and 3001. The primary objective of the ex-
tension studies was to evaluate the long-term safety and
tolerability of i.v.-administered bapineuzumab in sub-
jects with AD, as it is not known how the rate of adverse
events (AEs) and particularly ARIA-E evolves with the
duration of therapy beyond the term of the phase 3
studies. The 3002 study evaluated ApoE ε4 allele noncar-
riers and the 3003 study evaluated ApoE ε4 allele car-
riers. Additional exploratory evaluations of cognitive,




Both studies were phase 3, multicenter, long-term safety
and tolerability extension trials of i.v. bapineuzumab
once every 13 weeks in patients with AD. Prior to en-
rollment in either study, the protocols were reviewed
and approved by the appropriate institutional review
board or ethics committee, and all patients (or their le-
gally acceptable representative) and patient caregivers
provided informed consent. A complete list of all ethical
bodies that approved the ApoE ε4 carrier and ApoE ε4
noncarrier studies are listed in Additional files 1 and 2,
respectively. Both studies were conducted in accordance
with principles set forth in the Declaration of Helsinki
and according to good clinical practices established by
the International Conference on Harmonisation. The
3002 study enrolled ApoE ε4 noncarriers who had com-
pleted Study 3000. If they received bapineuzumab in the
main study, patients continued on bapineuzumab at the
same dose (either 0.5 or 1.0 mg/kg); if they received pla-
cebo, patients were randomized to receive either bapi-
neuzumab 0.5 mg/kg or 1.0 mg/kg. Patients who had
originally received the discontinued bapineuzumab
2.0 mg/kg dose in the parent study were reassigned to
1.0 mg/kg during that study and continued to receive
the 1.0 mg/kg dose in the extension study. All partici-
pants were aware that all patients were receiving
bapineuzumab in the 3002 study, while treatment as-
signment from the 3000 study remained blinded to pa-
tients and to site staff, including the dose. The 3003
study enrolled ApoE ε4 carriers who had completed
Study 3001. All patients were assigned to bapineuzumab
0.5 mg/kg whether they received bapineuzumab or
placebo in the parent study. All participants were
aware that all patients were receiving bapineuzumab
0.5 mg/kg, but treatment assignment from the 3001
study remained blinded to patients and to site staff.
The transition of patients who received placebo in the
parent studies to bapineuzumab treatment in the
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extension studies resulted in the formation of two sub-
groups: a bapineuzumab-to-bapineuzumab (bapineu-
zumab + bapineuzumab) “early start” group; and a
placebo-to-bapineuzumab (placebo + bapineuzumab)
“delayed start” group (Fig. 1). The initial planned dur-
ation of patient participation in the extension study
was 2 years, which was extended to 4 years (208 weeks)
per a protocol amendment dated July 2011. The first
patient enrolled in the ApoE ε4 noncarrier (3002)
study in February 2010 and in the ApoE ε4 carrier
(3003) study in December 2009. Both studies were ter-
minated in August 2012.
Inclusion criteria
Patients had to have been enrolled in the parent studies
(either 3000 or 3001) and completed all six infusions
specified in the parent protocol; if the study drug had
been suspended temporarily, the patients had to have
completed all visits through week 78 and be eligible to
resume investigational treatment. Patients met the inclu-
sion criteria for AD in the parent studies (3000 and
3001) if they had: a diagnosis of probable AD according
to the National Institute of Neurological and Communi-
cative Disorders and Stroke–Alzheimer’s Disease and
Related Disorders Association criteria; Rosen Modified
Hachinski Ischemic Score ≤ 4; Mini-Mental State Exam-
ination (MMSE) score of 16–26, inclusive; and a screen-
ing brain MRI scan consistent with the diagnosis of AD.
A brain MRI scan administered at week 71 of the parent
study had to be available for local and central radiologic
evaluation and remain consistent with a diagnosis of
AD. Patients also had to have had a MMSE score ≥10 at
screening (i.e., week 78 of the parent study). At each
study center, the protocol and informed consent form
and any amendments to these studies were reviewed and
approved by a duly constituted institutional review
board or independent ethics committee, and informed
consent was obtained before any screening procedures
specific to the extension studies were performed.
Main exclusion criteria
Patients were excluded if they had any medical or psy-
chiatric contraindication that, in the investigator’s opin-
ion, could increase the risks associated with the patient’s
continuation in or completion of the extension studies
or might preclude an evaluation of response. Patients
were also excluded if the brain MRI scan administered
at week 71 in the parent study (3000 or 3001) was indi-
cative of any significant abnormality, which for the ex-
tension studies included the following: four or more
microhemorrhages (<10 mm), history or evidence of a
single prior hemorrhage >1 cm3, two or more lacunar
infarcts, evidence of a single prior infarct >1 cm3, and
any abnormality detected in the MRI scan that was con-
sistent with exclusion criteria in the parent studies.
Concomitant AD medications
Patients who were receiving cholinesterase inhibitors or
memantine for AD in the parent study (3000 or 3001)
were allowed to continue at the same stable doses dur-
ing the extension studies (3002 or 3003). Experimental
medications for AD, all other experimental medications,
and the use of herbal preparations containing ginkgo
biloba were prohibited. Initiation of treatment with, or
change in stable doses of, drugs with the potential to
affect cognition, including cholinesterase inhibitors,
memantine, over-the-counter drugs, and nutritional sup-
plements, was prohibited unless medically indicated
(e.g., side effects due to such drugs required dose reduc-
tion, or use of such drugs was temporarily stopped and
restarted for medical reasons).
Fig. 1 Schematic of treatment group assignments between parent and extension studies. aDelayed-start treatment groups. PBO placebo
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Safety assessments
Both studies were continuously monitored by the same in-
dependent safety monitoring committee that functioned in
the parent studies. The safety variables assessed comprised
the incidence and severity of treatment-emergent AEs
(TEAEs) throughout the study; safety laboratory variables,
including clinical chemistry, hematology, and urinalysis (all
analyzed centrally), and serum anti-bapineuzumab anti-
body; clinically important changes in vital signs, weight,
and electrocardiograms (ECGs; with readings/interpreta-
tions performed centrally); and physical and neurological
examinations. Brain MRI scans were radiologically assessed
both centrally and locally. Both radiology reports were
reviewed by the investigator prior to subsequent investiga-
tional product infusion. After the first year, MRI scan fre-
quency was decreased from 13-week to 26-week intervals.
Other safety variables included suicidality assessment and
local reactions at the infusion site. ARIA-E, intraparenchy-
mal brain hemorrhage, seizure, and deep vein thrombosis
and/or pulmonary embolism (DVT/PE) were considered
AEs of special circumstance, to be reported within 24 hours
whether or not they were considered serious.
Exploratory efficacy and biomarker assessments
The following clinical efficacy variables were assessed
in both studies: ADAS-Cog/11, DAD, MMSE, and
Neuropsychiatric Inventory (NPI). Three health out-
comes measures were also explored: Dependence Scale,
Resource Utilization in Dementia-Lite version, and
Health Utilities Index. Biomarkers were assessed in a
subset of patients in both studies, including change
from baseline in cerebrospinal fluid (CSF), phosphory-
lated tau (p-tau), whole brain volume on volumetric
MRI (vMRI), and [11C]-Pittsburgh Compound B posi-
tron emission tomography (PiB-PET), as in the parent
studies.
Results
Patient disposition and exposure
Patient disposition and exposure in the 3002 and 3003
studies are presented in Table 1. In the ApoE ε4 carrier
study, 506 patients were screened and 492 patients
were enrolled; 216 patients had been randomized to
placebo in the parent study (3001) and thus were iden-
tified as the placebo + bapineuzumab 0.5 mg/kg group
(placebo + bapineuzumab 0.5), and 276 patients had ori-
ginally received bapineuzumab and thus were identified as
the bapineuzumab 0.5 mg/kg + bapineuzumab 0.5 mg/kg
group (bapineuzumab 0.5 + bapineuzumab 0.5). The safety
population was comprised of the 215 and 275 patients who
were treated in the placebo + bapineuzumab 0.5 and bapi-
neuzumab 0.5 + bapineuzumab 0.5 groups, respectively. In
Table 1 Patient disposition and exposure
ApoE ε4 carriers ApoE ε4 noncarriers
PBO + BAP 0.5 BAP 0.5 + BAP 0.5 PBO + BAP 0.5 BAP 0.5 + BAP 0.5 PBO + BAP 1.0 BAP 1.0 + BAP 1.0
Patients, n (%)
Randomized 216 (100) 276 (100) 39 (100) 66 (100) 37 (100) 56 (100)
Treated 215 (99.5) 275 (99.6) 39 (100) 66 (100) 37 (100) 56 (100)
Completeda 1 (0.5) 2 (0.7) 0 0 0 0
Withdrawn from treatment and/or studya 214 (99.5) 273 (99.3) 39 (100) 66 (100) 37 (100) 56 (100)
Primary reason for withdrawal from treatment (safety analysis population), n (%)
Unsatisfactory response-efficacy 3 (1.4) 6 (2.2) 1 (2.6) 1 (1.5) 2 (5.4) 2 (3.6)
Adverse event 16 (7.4) 11 (4.0) 2 (5.1) 5 (7.6) 2 (5.4) 6 (10.7)
Study termination 163 (75.8) 217 (78.9) 31 (79.5) 54 (81.8) 30 (81.1) 45 (80.4)
Subject request 19 (8.8) 25 (9.1) 1 (2.6) 4 (6.1) 3 (8.1) 3 (5.4)
Death 3 (1.4) 1 (0.4) 0 0 0 0
Recurrent episode of ARIA-E 1 (0.5) 0 0 0 0 0
All other reasonsb 9 (4.2) 13 (4.7) 4 (10.2) 2 (3.0) 0 0
Person-years of study drug exposurec
N 215 275 39 66 37 56
Mean (SD) 0.9 (0.58) 1.0 (0.58) 1.0 (0.53) 1.0 (0.61) 1.0 (5.4) 1.0 (5.4)
Median (range) 1 (0–3) 1 (0–3) 1 (0–2) 1 (0–3) 1 (0–2) 1 (0–2)
ApoE apolipoprotein E, ARIA-E amyloid-related imaging abnormalities with edema or effusions, BAP bapineuzumab, PBO placebo
aPercentage of treated patients
bIncludes investigator request, protocol violation, failed to return, lost to follow-up, loss of caregiver, other
cCalculated as the number of days for each individual patient from the day of the first infusion of the extension study through either the day of the last infusion
plus 137 days or the day of last study visit plus 1 day, whichever is shorter, divided by 365.25
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each treatment group, one patient was randomized but did
not actually receive a dose of study medication, which ac-
counts for the lower numbers in the safety population. The
principle reason for withdrawal from treatment was spon-
sor decision; 76 % in the placebo + bapineuzumab 0.5 group
and 79 % in the bapineuzumab 0.5 + bapineuzumab 0.5
group were withdrawn from treatment because the spon-
sors discontinued the study. Another 7 % and 4 % of pa-
tients, respectively, withdrew because of AEs. The mean
number of person-years of exposure during this ApoE ε4
carrier extension study was 0.9 and 1.0, respectively.
In the ApoE ε4 noncarrier study, 209 patients were
screened and 202 patients were enrolled. All patients with-
drew from treatment, and none completed the study. Ap-
proximately 80 % of patients across treatment groups were
withdrawn from treatment because the sponsor discontin-
ued the study; across the groups, a total of 15 patients
(7.4 %) withdrew because of AEs. The mean number of
person-years of exposure during this extension study was
1.0 year in all groups. The number enrolled in the noncar-
rier study is notably lower than in the carrier study because
enrollment in the parent study was much slower than in
the parent carrier study. In addition, only 40 % of patients
in the parent noncarrier study had completed the study at
the time of early termination compared with over 60 % of
patients in the parent carrier study. All enrolled patients
were treated and included in the safety analysis population
(n = 39 and n = 37 for the original placebo patients who
were randomized to the placebo + bapineuzumab 0.5 and
placebo + bapineuzumab 1.0 groups, respectively; n = 66
and n = 56 for the bapineuzumab 0.5 + bapineuzumab 0.5
and bapineuzumab 1.0 + bapineuzumab 1.0 groups, re-
spectively; and an additional four patients who were
transitioned from 2.0 mg/kg to 1.0 mg/kg in the parent
noncarrier study who were included in the safety popula-
tion but not in the other analyses).
Demographics and baseline characteristics
Demographics and baseline characteristics for the safety
population in both studies are presented in Tables 2 and
3. At the beginning of the extension study most patients
were using cholinesterase inhibitors and/or memantine.
Among ApoE ε4 carriers, 79 % had a single ApoE ε4 al-
lele. The demographics at the beginning of the extension
study were close to those observed at the baseline of the
parent study across treatment groups. As expected, pa-
tients entering the extension study had a longer duration
of AD than those beginning the parent study, approxi-
mately 4.4 years vs 2.9 years; mean MMSE scores were
lower at the beginning of the extension study compared
with baseline MMSE in the parent study.
In ApoE ε4 carriers (Study 3003), the mean age at the
beginning of the extension study (Table 3) was similar be-
tween groups. Most patients were white; 20.8 % were
Asian. More than half were female and the mean duration
of AD was 4.49 and 4.58 years in the placebo + bapineuzu-
mab and bapineuzumab + bapineuzumab groups, respect-
ively. Baseline MMSE scores were 19.0 and 19.2,
respectively, at the beginning of the extension study.
In ApoE ε4 noncarriers (Study 3002), the mean age at
the beginning of the extension study was also similar be-
tween groups (Table 3). Most patients were white,
25.2 % were Asian, and more than half of the patients
were female. Across treatment groups, the mean dur-
ation of AD was 4.38 years at the beginning of the ex-
tension study, and the mean MMSE score was 18.4.
Table 2 Patient demographics and baseline characteristics at study entry (parent study safety population)
3001 ApoE ε4 carrier study 3000 ApoE ε4 noncarrier study
PBO (n = 215) BAP 0.5 (n = 275) PBO (n = 76) BAP 0.5 (n = 66) BAP 1.0 (n = 56)
Mean age (years) 69.8 70.6 67.3 69.8 68.9
Femalea (%) 62.3 67.6 61.8 53.0 62.5
Whitea (%) 80.9 75.3 78.9 74.2 66.1
Asian (%) 18.1 22.9 21.1 25.8 32.1
Mean duration of AD (years) 2.89 2.98 2.73 2.85 2.87
Mean baseline MMSE 21.3 21.4 20.2 20.8 20.6
Current AChEI and/or memantine use, n (%)
Yes 199 (92.6) 255 (92.7) 70 (92.1) 56 (84.8) 54 (96.4)
No 16 (7.4) 20 (7.3) 6 (7.9) 10 (15.2) 2 (3.6)
ApoE ε4 allele count, n (%)
1 171 (79.5) 217 (78.9) NA NA NA
2 44 (20.5) 58 (21.1) NA NA NA
AChEI acetylcholinesterase inhibitor, AD Alzheimer’s disease, ApoE apolipoprotein E, BAP bapineuzumab, MMSE Mini-Mental State Examination, NA not applicable,
PBO placebo
aA few patients may have been misclassified at baseline, causing discrepancy with Table 3: one patient was classified as male at parent baseline and female at
extension baseline; three patients were classified as white at parent baseline and Asian or “other” at extension baseline
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Safety
Overall, the percentages of TEAEs, serious AEs (SAEs),
TEAEs leading to early termination from the study,
TEAEs leading to early termination from treatment, and
TEAEs leading to dose reduction or temporary discon-
tinuation were similar for patients in the carrier (3003)
and noncarrier (3002) studies (Table 4). In the bapineu-
zumab 2.0 + bapineuzumab 1.0 group (not shown in the
tables), no SAEs were reported and eight TEAEs were
reported in three patients (75 %), all of which were of
mild intensity and none of these events were considered
by the investigator to be related to study treatment.
TEAEs
TEAEs for the carrier and noncarrier studies are shown
in Tables 5 and 6, respectively. In ApoE ε4 carriers
(Study 3003), TEAEs were reported in 152 patients
(70.7 %) in the placebo + bapineuzumab 0.5 group and
184 patients (66.9 %) in the bapineuzumab 0.5 + bapi-
neuzumab 0.5 group. The most common TEAEs occur-
ring in ≥5 % regardless of causality were ARIA-E,
cerebral microhemorrhage, headache, diarrhea, urinary
tract infection, and anxiety. ARIA-E and cerebral micro-
hemorrhage had different reporting requirements, so pa-
tients may have had either one or both.
In ApoE ε4 noncarriers (Study 3002), TEAEs were
reported in 32 (82.1 %) of those in the placebo + bapi-
neuzumab 0.5 group, 25 of those (67.6 %) in the pla-
cebo + bapineuzumab 1.0 group, 48 of those (72.7 %)
in the bapineuzumab 0.5 + bapineuzumab 0.5 group,
and 36 of those (64.3 %) in the bapineuzumab 1.0 +
bapineuzumab 1.0 group. The most common TEAEs
occurring in ≥5 % regardless of causality were ARIA-
E, urinary tract infection, headache, gastroenteritis,
nasopharyngitis, delusion, gait disturbance, and fall
(Table 6).
TEAEs leading to treatment discontinuation or study
discontinuation
Patients who had to discontinue use of study medication
were encouraged to continue to attend scheduled study
visits and undergo applicable procedures if feasible. In
Table 3 Patient demographics and baseline characteristics from extension study baseline
3003 ApoE ε4 carrier study 3002 ApoE ε4 noncarrier study
PBO + BAP 0.5
(n = 215)
BAP 0.5 + BAP 0.5
(n = 275)
PBO + BAP 0.5
(n = 39)
PBO + BAP 1.0
(n = 37)
BAP 0.5 + BAP 0.5
(n = 66)
BAP 1.0 + BAP 1.0
(n = 56)
Mean age (years) 71.4 72.1 68.7 68.9 71.4 70.6
Femalea (%) 62.8 67.6 64.1 59.5 53.0 62.5
Whitea (%) 79.5 75.6 76.9 81.1 74.2 66.1
Asian (%) 18.1 22.9 23.1 18.9 25.8 32.1
Mean duration of AD (years) 4.49 4.58 4.16 4.50 4.44 4.46
Mean baseline MMSE 19.0b 19.2 18.6c 17.1 19.1 18.4
Current AChEI and/or memantine use, n (%)
Yes 193 (89.8) 242 (88.0) 34 (87.2) 31 (83.8) 51 (77.3) 53 (94.6)
No 22 (10.2) 33 (12.0) 5 (12.8) 6 (16.2) 15 (22.7) 3 (5.4)
AChEI acetylcholinesterase inhibitor, AD Alzheimer’s disease, ApoE apolipoprotein E, BAP bapineuzumab, MMSE Mini-Mental State Examination, PBO placebo
aA few patients may have been misclassified at baseline, causing discrepancy with Table 2: one patient was classified as male at parent baseline and female at
extension baseline; three patients were classified as white at parent baseline and Asian or “other” at extension baseline
bn = 212
cn = 38
Table 4 Overview of treatment-emergent adverse events in the safety population
3003 ApoE ε4 carrier study 3002 ApoE ε4 noncarrier study
PBO + BAP 0.5
(n = 215)
BAP 0.5 + BAP 0.5
(n = 275)
PBO + BAP 0.5
(n = 39)
PBO + BAP 1.0
(n = 37)
BAP 0.5 + BAP
0.5 (n = 66)
BAP 1.0 + BAP
1.0 (n = 56)
Any TEAE 152 (70.7) 184 (66.9) 32 (82.1) 25 (67.6) 48 (72.7) 36 (64.3)
Any SAE 35 (16.3) 33 (12.0) 6 (15.4) 1 (2.7) 10 (15.2) 11 (19.6)
TEAE leading to treatment
discontinuation
18 (8.4) 10 (3.6) 2 (5.1) 2 (5.4) 5 (7.6) 6 (10.7)
TEAE leading to study discontinuation 14 (6.5) 10 (3.6) 2 (5.1) 1 (2.7) 1 (1.5) 1 (1.8)
TEAE leading to dose reduction or
temporary discontinuation
18 (8.4) 10 (3.6) 2 (5.1) 3 (8.1) 1 (1.5) 4 (7.1)
Data presented as n (%)
ApoE apolipoprotein E, BAP bapineuzumab, PBO placebo, SAE serious adverse event, TEAE treatment-emergent adverse event
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ApoE ε4 carriers, TEAEs led to treatment discontinuation
in <10 % of patients and study discontinuation in <7 % of
patients in either group; these numbers were higher in the
placebo + bapineuzumab 0.5 group than in the bapineuzu-
mab 0.5 + bapineuzumab 0.5 group (Table 4).
In ApoE ε4 noncarriers, TEAEs led to treatment
discontinuation in <11 % of patients in any treat-
ment group, and the numbers were lowest in the
placebo + bapineuzumab groups and highest in the
bapineuzumab 1.0 + bapineuzumab 1.0 group. TEAEs
leading to study discontinuation occurred in <6 % of
patients in any treatment group, and the numbers
were higher in the placebo + bapineuzumab groups
(Table 4).
SAEs and deaths
In ApoE ε4 carriers, there were five deaths (2.3 %) in the
placebo + bapineuzumab 0.5 group (cardiac failure, me-
tastases to lymph nodes, ovarian cancer, pancreatic car-
cinoma, subarachnoid hemorrhage) and two deaths
(0.7 %) in the bapineuzumab 0.5 + bapineuzumab 0.5
group (cardiac failure congestive and cardiomyopathy).
Of these, one death was due to a TEAE assessed as re-
lated to bapineuzumab treatment by the study investiga-
tor (subarachnoid hemorrhage in the placebo +
bapineuzumab 0.5 group). The corresponding rates of
treatment-emergent SAEs in these treatment groups
were 16.3 % and 12.0 %, respectively.
In ApoE ε4 noncarriers, there were no deaths.
Treatment-emergent SAEs occurred in six patients
(15.4 %) in the placebo + bapineuzumab 0.5 group, 10
patients (15.2 %) in the bapineuzumab 0.5 + bapineuzu-
mab 0.5 group, one patient (2.7 %) in the placebo + bapi-
neuzumab 1.0 group, and 11 patients (19.6 %) in the
bapineuzumab 1.0 + bapineuzumab 1.0 group.
AEs of special circumstance
In ApoE ε4 carriers (Study 3003), ARIA-E was reported as
a TEAE in 23 patients (10.7 %) in the placebo + bapineuzu-
mab 0.5 group and 10 patients (3.6 %) in the bapineuzumab
0.5 + bapineuzumab 0.5 group. ARIA-E was asymptomatic
in 16 (7.4 %) and nine (3.3 %) patients in the two treatment
groups, respectively. ARIA-E was reported as a treatment-
emergent SAE in six patients (2.8 %) in the placebo +
Table 6 Treatment-emergent adverse events (≥5 % in any group), safety population: noncarrier study
Event PBO + BAP 0.5 (n = 39) BAP 0.5 + BAP 0.5 (n = 66) PBO + BAP 1.0 (n = 37) BAP 1.0 + BAP 1.0 (n = 56)
ARIA-E (vasogenic cerebral edema) 3 (7.7) 2 (3.0) 6 (16.2) 3 (5.4)
Urinary tract infection 2 (5.1) 7 (10.6) 1 (2.7) 0
Headache 1 (2.6) 1 (1.5) 3 (8.1) 2 (3.6)
Gastroenteritis 0 0 3 (8.1) 0
Nasopharyngitis 3 (7.7) 1 (1.5) 1 (2.7) 2 (3.6)
Delusion 3 (7.7) 3 (4.5) 0 0
Gait disturbance 3 (7.7) 0 1 (2.7) 0
Fall 0 3 (4.5) 2 (5.4) 4 (7.1)
Dizziness 1 (2.6) 4 (6.1) 0 0
Cerebral microhemorrhage 0 1 (1.5) 0 3 (5.4)
Cognitive disorder 1 (2.6) 2 (3.0) 2 (5.4) 3 (5.4)
Depression 0 0 2 (5.4) 0
Subdural hematoma 0 0 0 3 (5.4)
Aggression 2 (5.1) 0 0 0
Anemia 2 (5.1) 1 (1.5) 0 0
Cough 2 (5.1) 0 0 2 (3.6)
Nausea 2 (5.1) 0 0 0
Data presented as n (%)
ARIA-E amyloid-related imaging abnormalities with edema or effusions, BAP bapineuzumab, PBO placebo
Table 5 Treatment-emergent adverse events (≥5 % in either
group), safety population: carrier study
Event PBO + BAP 0.5
(n = 215)
BAP 0.5 + BAP 0.5
(n = 275)
ARIA-E (vasogenic cerebral edema) 23 (10.7) 10 (3.6)
Cerebral microhemorrhage 20 (9.3) 15 (5.5)
Headache 16 (7.4) 8 (2.9)
Diarrhea 12 (5.6) 10 (3.6)
Urinary tract infection 12 (5.6) 9 (3.3)
Anxiety 11 (5.1) 7 (2.5)
Data presented as n (%)
ARIA-E amyloid-related imaging abnormalities with edema or effusions, BAP
bapineuzumab, PBO placebo
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bapineuzumab 0.5 group and two patients (0.7 %) in the
bapineuzumab 0.5 + bapineuzumab 0.5 group. In the ApoE
ε4 noncarriers (Study 3002), ARIA-E was reported as a
TEAE in three patients (7.7 %) in the placebo + bapineuzu-
mab 0.5 group, two patients (3.0 %) in the bapineuzumab
0.5 + bapineuzumab 0.5 group, six patients (16.2 %) in the
placebo + bapineuzumab 1.0 group, and three patients
(5.4 %) in the bapineuzumab 1.0 + bapineuzumab 1.0
group; overall, the percentage was greater in the placebo +
bapineuzumab groups (11.8 %) than in the bapineuzumab
+ bapineuzumab groups (4.1 %). All were asymptomatic ex-
cept for one patient in the placebo + bapineuzumab 0.5
group. ARIA-E was reported as a treatment-emergent SAE
in two patients, one patient in each of the placebo + bapi-
neuzumab groups, and no patients in either of the bapineu-
zumab + bapineuzumab groups.
In the carrier study, intracranial hemorrhage (including
intraparenchymal brain hemorrhage, subdural, intraventric-
ular, and subarachnoid bleeding, but excluding microhe-
morrhages or larger hemosiderin deposits) was reported as
a TEAE in six patients (2.8 %) in the placebo + bapineuzu-
mab 0.5 group and none in the bapineuzumab 0.5 + bapi-
neuzumab 0.5 group. One cerebral hemorrhage and two
subarachnoid hemorrhages were reported as treatment-
emergent SAEs; one subarachnoid hemorrhage was fatal. In
the noncarrier study, intracranial hemorrhage was reported
as a TEAE in one patient in the bapineuzumab 0.5 + bapi-
neuzumab 0.5 group, three patients in the bapineuzumab
1.0 + bapineuzumab 1.0 group, and no patients in either of
the placebo + bapineuzumab groups. One subarachnoid
hemorrhage in the bapineuzumab 0.5 + bapineuzumab 0.5
group was reported as a treatment-emergent SAE.
In the carrier study, seizure/convulsion was reported
in four patients (1.9 %) in the placebo + bapineuzumab
0.5 group and three patients (1.1 %) in the bapineuzu-
mab 0.5 + bapineuzumab 0.5 group. In the noncarrier
study, seizure/convulsion was reported in one patient
(2.6 %) in the placebo + bapineuzumab 0.5 group, one
patient (1.5 %) in the bapineuzumab 0.5 + bapineuzumab
0.5 group, one patient (2.7 %) in the placebo + bapineu-
zumab 1.0 group, and no patients in the bapineuzumab
1.0 + bapineuzumab 1.0 group.
DVT/PE was reported in one patient in the placebo +
bapineuzumab 0.5 group in the carrier study and two
patients in the bapineuzumab 0.5 + bapineuzumab 0.5
group in the noncarrier study.
Exploratory assessments
Overall, the changes in scores were similar between the
dose groups across cognitive, functional, and behavioral
measures in both studies. None of the health outcomes
measures showed any significant differences in either
study. The least-squares (LS) mean change in ADAS-
Cog/11 and DAD scores from parent study baseline to
extension study week 52 were not significantly different
between treatment groups in either the ApoE ε4 carriers
(Study 3003) or ApoE ε4 noncarriers (Study 3002)
(Tables 7 and 8). In the carrier study, the between-group
difference in ADAS-Cog/11 score change from baseline
was 0.0 (P = 0.996) and the between-group difference in
DAD score change from baseline was –1.75 (P = 0.412).
NPI and MMSE scores were not significantly different in
changes from baseline (Table 7). Similarly, in the non-
carrier study the between-group difference in LS mean
change in ADAS-Cog/11 score between the placebo +
bapineuzumab 0.5 and bapineuzumab 0.5 + bapineuzumab
0.5 groups was –2.05 (P = 0.345); and between the pla-
cebo + bapineuzumab 1.0 and bapineuzumab 1.0 + bapi-
neuzumab 1.0 groups, the difference was –0.22 (P = 0.922).
The between-group difference in LS mean change in DAD
scores between the placebo + bapineuzumab 0.5 and
bapineuzumab 0.5 + bapineuzumab 0.5 groups was
1.53 (P = 0.733); and between the placebo + bapineuzu-
mab 1.0 and bapineuzumab 1.0 + bapineuzumab 1.0
groups, the difference was –2.81 (P = 0.550). NPI and
MMSE scores were also not significantly different in
changes from baseline (Table 8).
In both the ApoE ε4 carrier and noncarrier studies, only
a very limited amount of data was obtained for the bio-
marker studies because of the premature discontinuation of
the study by the sponsor. The PiB-PET analysis population
patients (who had standardized uptake value ratio ≥ 1.35 at
baseline in the parent study and a postbaseline assessment
in the extension study) comprised one patient in the carrier
study and two patients in the noncarrier study. For the CSF
biomarker substudy, 15 patients were enrolled in the carrier
study and 14 patients in the noncarrier study; no significant
differences in CSF p-tau were observed in either study. In
Table 7 Carrier study exploratory clinical efficacy assessments:
change from parent study baseline to extension week 52
3003 ApoE ε4 carrier study
PBO + BAP 0.5
(n = 199)
BAP 0.5 + BAP 0.5
(n = 256)
ADAS-Cog, LS mean (SE) 10.12 (0.75) 10.11 (0.63)
LS mean difference 0.00; P = 0.996
DAD, LS mean (SE) –20.96 (1.65) –22.72 (1.36)
LS mean difference –1.75; P = 0.412
NPI, LS mean (SE) 4.32 (0.96) 3.52 (0.80)
LS mean difference –0.80; P = 0.524
MMSEa, LS mean (SE) –4.44 (0.26) –4.26 (0.21)
LS mean difference 0.18; P = 0.598
ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive Subscale, ApoE
apolipoprotein E, BAP bapineuzumab, DAD Disability Assessment Scale for
Dementia, LS least squares, MMSE Mini-Mental State Examination, NPI
Neuropsychiatric Inventory, PBO placebo, SE standard error of the mean
aDifference in MMSE score was between parent study baseline and extension
study week 45
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the vMRI substudy, 26 patients in the combined placebo +
bapineuzumab group and 35 patients in the combined
bapineuzumab + bapineuzumab group in the noncarrier
study had assessments of whole brain volume at extension
study baseline and week 45. The LS mean change and
standard error of the mean (SE) were –30.2 (8.1) in the pla-
cebo + bapineuzumab group and –12.6 (6.8) in the bapi-
neuzumab + bapineuzumab group, for a difference of 17.5
(P = 0.111). Fifty-one patients in the placebo + bapineuzu-
mab group and 78 patients in the bapineuzumab +
bapineuzumab group in the carrier study had assessments
of whole brain volume at extension study baseline and
week 45. The LS mean change and SE were –60.28 (21.94)
in the placebo + bapineuzumab group and –38.67 (17.88) in
the bapineuzumab + bapineuzumab group, for a difference
of 21.61 (P = 0.447).
Discussion
The present studies examined the safety of long-term
treatment with bapineuzumab in patients with AD who
participated in the parent studies 3000 and 3001. As
such, they are among the first studies to report the safety
of regular dosing of a mAb against Aβ over a period of
approximately 3.5 years.
Safety
Infusion of bapineuzumab 0.5 or 1.0 mg/kg every 13 weeks
for up to 3.5 years was generally well tolerated, with a safety
and tolerability profile that was similar to that observed in
previous studies. The long-term safety and tolerability pro-
file was generally similar in ApoE ε4 noncarriers and car-
riers in the extension studies, except for a higher incidence
proportion of treatment-emergent death in carriers. There
was a higher incidence proportion of ARIA-E (vasogenic
edema) observed with onset during the study in both non-
carrier and carrier patients who first received bapineuzu-
mab in the extension studies than in those who had
received bapineuzumab from the beginning of the parent
studies. This finding further supports the observations dur-
ing the double-blind studies that ARIA-E tends to occur
early in the course of bapineuzumab exposure (most often
between infusions 1 and 3) [7], with a decline in the inci-
dence of ARIA-E over time with continued bapineuzumab
exposure during the double-blind studies. This finding is
consistent with a reduced risk of ARIA-E after longer ex-
posure. However, in patients who continued on bapi-
neuzumab in both extension studies, ARIA-E was still
seen after the sixth dose in 3.6 % of carriers and 4.1 %
of noncarriers, and the latest ARIA-E occurred after
the twelfth dose of bapineuzumab. There was also evi-
dence of a dose effect for ARIA-E in the noncarrier
study, consistent with previous studies, which demon-
strated that the risk of ARIA-E increased with bapi-
neuzumab dose [7].
Efficacy
To date, a clinical benefit of amyloid-targeted immunother-
apy with bapineuzumab or any other mAb has not been ob-
served for patients with AD [7, 10]. Recently reported
findings from pivotal phase 3 studies of bapineuzumab in
patients with mild to moderate AD failed to show a signifi-
cant difference in clinical endpoints of ADAS-Cog/11 and
DAD scores or other clinical endpoints [7]. Among ApoE
ε4 carriers (but not noncarriers), bapineuzumab was associ-
ated with reduced CSF p-tau concentrations, a marker of
neurodegeneration. Carriers also showed a decrease in
amyloid accumulation based on PiB-PET findings. Similarly,
another mAb, solanezumab, which preferentially binds to
soluble forms of Aβ, also failed to improve clinical parame-
ters in patients with mild to moderate AD in the phase 3
trials [10]. Gantenerumab, a fully human mAb that binds to
two regions of monomeric and fibrillar Aβ, reduced brain
amyloid burden in a multiple ascending dose study, find-
ings that were not correlated with cognitive measures [11].
In the long-term extension studies reported here, the bio-
marker subpopulations were too small to support
Table 8 Noncarrier study exploratory clinical efficacy assessments: change from parent study baseline to extension week 52
3002 ApoE ε4 noncarrier study
PBO + BAP 0.5 (n = 38) BAP 0.5 + BAP 0.5 (n = 62) PBO + BAP 1.0 (n = 33) BAP 1.0 + BAP 1.0 (n = 53)
ADAS-Cog, LS mean (SE) 12.44 (1.70) 10.38 (1.35) 10.54 (1.82) 10.31 (1.36)
LS mean difference –2.05; P = 0.345 –0.22; P = 0.922
DAD, LS mean (SE) –29.52 (3.48) –28.00 (2.77) –20.41 (3.74) –23.21 (2.80)
LS mean difference 1.53; P = 0.733 –2.81; P = 0.550
NPI, LS mean (SE) 4.99 (2.60) –0.01 (2.05) 4.23 (2.80) 6.57 (2.08)
LS mean difference –4.99; P = 0.133 2.34; P = 0.505
MMSEa, LS mean (SE) –4.86 (0.56) –4.13 (0.44) –4.63 (0.58) –4.51 (0.46)
LS mean difference 0.73; P = 0.309 0.12; P = 0.872
ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive Subscale, ApoE apolipoprotein E, BAP bapineuzumab, DAD Disability Assessment Scale for Dementia,
LS least squares, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory, PBO placebo, SE standard error of the mean
aDifference in MMSE score was between parent study baseline and extension study week 45
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substantial analyses. The results for ADAS-Cog/11 and
DAD were similar for carriers and noncarriers, showing de-
clining cognition (ADAS-Cog/11) and function (DAD) con-
sistent with AD progression over time [12]. They were also
similar between the two dose groups in the noncarrier
study, suggesting no adverse effect of the higher dose on
cognitive measures. Despite the lack of efficacy in patients
with mild to moderate AD, it has been speculated that the
earlier use of these therapies in mild AD, or in asymptom-
atic patients with Aβ accumulation, may be of benefit [7,
10, 13]. It is unknown whether the use of immunotherapy
earlier in the disease process, perhaps before the onset of
disability (early AD or pre-AD), will result in clinical
benefit [7, 10, 13], and whether such a population can
be identified. These studies provide some evidence to
support the safety and tolerability of the long-term ad-
ministration of anti-Aβ therapy, which would be use-
ful when treating earlier in the disease process.
Study limitations
The studies described herein have several limitations, in-
cluding the lack of a placebo control in the extension
groups and the fact that they were not fully randomized.
Early discontinuation of the trials affected the number of
patients available for the exploratory clinical efficacy and
health outcomes analyses, as well as the biomarker ana-
lyses (CSF, PiB-PET, vMRI).
Conclusions
The i.v. infusion of bapineuzumab 0.5 mg/kg to ApoE ε4
carriers or of bapineuzumab 0.5 mg/kg or 1.0 mg/kg to
ApoE ε4 noncarriers every 13 weeks for up to 3.5 years
was generally well tolerated. The safety and tolerability
profile of bapineuzumab was similar to that observed in
previous studies of bapineuzumab, and no new or unex-
pected safety concerns were identified.
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